<?xml version="1.0" encoding="UTF-8"?>
<p>Two clinical trials have been completed. The initial study, a phase 1 safety, immunogenicity and dose-ranging trial in 24 healthy adults in Spain, triggered a vaccine-specific immunological response against several 
 <italic>Mtb</italic> antigens, without significant toxicity, supporting further development 
 <sup>
  <xref rid="ref-54" ref-type="bibr">54</xref>
 </sup>. The second study was a phase 2 safety, immunogenicity and dose ranging trial in 48 HIV+ and 48 HIV- persons with LTBI in South Africa 
 <sup>
  <xref rid="ref-53" ref-type="bibr">53</xref>
 </sup>. These studies demonstrated a good cellular polyantigenic response after a first injection of 25 mcg in both HIV- and HIV+ participants and elicited a long-term memory surrogate response compatible with a prophylactic potential already observed in animal models.
</p>
